Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references Exhibit 99.1 for Iovance’s fiscal-year results and related disclosures.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references Exhibit 99.1 for Iovance’s fiscal-year results and related disclosures
- Exhibit 99.1 is furnished, not filed under Exchange Act Section 18, limiting associated liability
- Information is not automatically incorporated into future Securities Act or Exchange Act filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $99.3M, up 66% YoY and 39% sequentially, signaling accelerating Amtagvi commercialization
- U.S. Amtagvi revenue ~$91M, up 40% from 4Q25, with gross margin reaching 56%
- FY26 revenue guidance of $350M-$370M under review, creating potential near-term estimate upside
- FDA Fast Track designation for lifileucel in soft tissue sarcomas expands the pipeline beyond melanoma
- Cash ~$304M supports operations into 2H28, reducing near-term financing risk despite a $47.3M quarterly net loss
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.